Myasthenia Gravis (MG) operates as a rare autoimmune disorder that compromises neuromuscular junction signaling, resulting in characteristic muscle fatigue and progressive weakness manifestations. The global myasthenia gravis therapeutic ecosystem exhibits substantial growth potential, driven by sophisticated diagnostic advancements, heightened clinical recognition, and innovative treatment...
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt